Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
3 Italian City Cars That Outsmarted Regulations and Rivals - 2Hundreds rally in West Bank against Israeli death penalty for Palestinians
- 32 bright planets light up April evenings — here's where and when to look
- 4Instructions to Warmly greet Certainty and Appeal
- 5Climate change is straining Alaska's Arctic. A new mining road may push the region past the brink
- Activists Took BMW and Mercedes to Court Over Gas Cars. It Didn’t Stick
- IDF carried out mission to locate former hostage Avera Mengistu a day before Oct. 7
- Vote in favor of your Favored kind of pasta
- Getting through a Lifelong Change: Individual Examples of overcoming adversity
- How a toxic self-improvement trend with a funny name took over your feed
- NASA chief Jared Isaacman says Texas may get a moonship, not space shuttle Discovery
- This Tiny Neon Frog Dwells in the Clouds
- Quandoo to shut restaurant booking platform by end of 2026
- US FDA panel to weigh bid to market nicotine pouches as lower-risk than cigarettes
